Endosomal processing limits gene transfer to polarized airway epithelia by adeno-associated virus
Open accessThe DOI matches its Crossref record; 43 of the 45 references it cites were found in a registry or an index.
Abstract
The restriction of viral receptors and coreceptors to the basolateral surface of airway epithelial cells has been blamed for the inefficient transfer of viral vectors to the apical surface of this tissue. We now report, however, that differentiated human airway epithelia internalize rAAV type-2 virus efficiently from their apical surfaces, despite the absence of known adeno-associated virus-2 (AAV-2) receptors or coreceptors at these sites. The dramatically lower transduction efficiency of rAAV infection from the apical surface of airway cells appears to result instead from differences in endosomal processing and nuclear trafficking of apically or basolaterally internalized virions. AAV capsid proteins are ubiquitinated after endocytosis, and gene transfer can be significantly enhanced by proteasome or ubiquitin ligase inhibitors. Tripeptide proteasome inhibitors increased persistent rAAV gene delivery from the apical surface >200-fold, to a level nearly equivalent to that achieved with basolateral infection. In vivo application of proteasome inhibitor in mouse lung augmented rAAV gene transfer from undetectable levels to a mean of 10.4 +/- 1.6% of the epithelial cells in large bronchioles. Proteasome inhibitors also increased rAAV-2-mediated gene transfer to the liver tenfold, but they did not affect transduction of skeletal or cardiac muscle. These findings suggest that tissue-specific ubiquitination of viral capsid proteins interferes with rAAV-2 transduction and provides new approaches to circumvent this barrier for gene therapy of diseases such as cystic fibrosis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In vitro and preclinical animal studies have shown administration of bortezomib prevents degradation of internalized AAVs, reduces capsid presentation, and increases transduction efficiency by enhancing nuclear translocation of AAV [165, 224, 225].”
From Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer (2023) · cites this paper as [224]
In the citing paper
“After entry into cells, AAV cells can be ubiquitinated for degradation in proteasomes (91), generating increased amount of antigens for immune activation.”
From A versatile toolkit for overcoming AAV immunity (2022) · cites this paper as [91]
In the citing paper
“AAV capsids undergo proteosome-mediated degradation in the cytoplasm, which may expose the packaged genomes to cytoplasmic DNA sensors.”
From Innate immune sensing of adeno-associated virus vectors (2024) · cites this paper as [43]
Citations
Cites
Rock, K. L., Gramm, C., Rothstein, L., Clark, K., Stein, R., Dick, L., Hwang, D., & Goldberg, A. L. (1994) · Cell · doi:10.1016/s0092-8674(94)90462-6 · Cited by 2,524 · cited 1×
“Several specific, cellpermeable, peptide aldehyde inhibitors of proteasome pathways have recently been discovered (30, 31).”
BackgroundFenteany, G., Standaert, R. F., Lane, W. S., Choi, S., Corey, E. J., & Schreiber, S. L. (1995) · Science · doi:10.1126/science.7732382 · Cited by 1,583 · cited 1×
“Several specific, cellpermeable, peptide aldehyde inhibitors of proteasome pathways have recently been discovered (30, 31).”
BackgroundSummerford, C., & Samulski, R. J. (1998) · Journal of Virology · doi:10.1128/jvi.72.2.1438-1445.1998 · Cited by 1,406 · cited 1×
“Recently, the heparin sulfate proteoglycan receptor (3), and FGFR-1 (4) and αVβ5 integrin (5) coreceptors for AAV-2, have been localized to the basolateral membrane of polarized airway epithelial cells (6, 7).”
BackgroundMultiple proteolytic systems, including the proteasome, contribute to CFTR processing
Jensen, T. J., Loo, M. A., Pind, S., Williams, D. B., Goldberg, A. L., & Riordan, J. R. (1995) · Cell · doi:10.1016/0092-8674(95)90241-4 · Cited by 897 · cited 18×
“A similar result was achieved when another ubiquitinproteasome pathway inhibitor, Z-LLL (33), was tested (data not shown).”
BackgroundInfluentialαVβ5 integrin: a co-receptor for adeno-associated virus type 2 infection
Summerford, C., Bartlett, J. S., & Samulski, R. J. (1999) · Nature Medicine · doi:10.1038/4768 · Cited by 711
Fisher, K. J., Gao, G. P., Weitzman, M. D., DeMatteo, R., Burda, J. F., & Wilson, J. M. (1996) · Journal of Virology · doi:10.1128/jvi.70.1.520-532.1996 · Cited by 547 · cited 2×
“Alternative approaches have attempted to increase transgene expression by enhancing the molecular conversion of nonfunctional viral genomes to expressible forms, as in the case of rAAV (12, 13), or by increasing transcription and translation efficiency by altering the transgene expression cassettes (14).”
BackgroundDuan, D., Sharma, P., Yang, J., Yue, Y., Dudus, L., Zhang, Y., Fisher, K. J., & Engelhardt, J. F. (1998) · Journal of Virology · doi:10.1128/jvi.72.11.8568-8577.1998 · Cited by 522 · cited 2×
“It has been previously shown that AAV transduction in certain tissues such as muscle and retina is very efficient (16, 38), whereas other tissues including lung and liver are less favorably transduced (6, 39).”
BackgroundMethodSelf-citationThe Ubiquitin-Proteasome Pathway and Pathogenesis of Human Diseases
Schwartz, P., & Ciechanover, M. (1999) · Annual Review of Medicine · doi:10.1146/annurev.med.50.1.57 · Cited by 466 · cited 2×
“Regulated intracellular proteolysis through proteasomes plays a critical role in many physiological and pathological conditions (35).”
BackgroundSamulski, R. J., Chang, L. S., & Shenk, T. (1987) · Journal of Virology · doi:10.1128/jvi.61.10.3096-3101.1987 · Cited by 449 · cited 1×
“The entire β-galactosidase expression cassette, including the RSV promoter, β-galactosidase reporter gene, and SV40 polyA signal, was excised by Sal I digestion and subsequently cloned into the pSub201 backbone by blunt-end ligation (18).”
MethodHuman fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2
Qing, K., Mah, C., Hansen, J., Zhou, S., Dwarki, V., & Srivastava, A. (1999) · Nature Medicine · doi:10.1038/4758 · Cited by 443
Research works printed but not linked: 3
- Zabner, 1996, Gene Ther, 3, 458
- Hughes, 1993, Lab Invest, 69, 173
- Bennett, 1997, Invest Ophthalmol Vis Sci, 38, 2857
Cited by
Pathophysiology and Management of Pulmonary Infections in Cystic Fibrosis
Gibson, R. L., Burns, J. L., & Ramsey, B. W. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200304-505so · Cited by 1,633
“Coadministration of AAV2 with a proteosome inhibitor (449) results in improved transgene expression and augmented nuclear trafficking of the virus.”
BackgroundAdeno-Associated Virus (AAV) as a Vector for Gene Therapy
Naso, M. F., Tomkowicz, B., Perry, W. L., & Strohl, W. R. (2017) · BioDrugs · doi:10.1007/s40259-017-0234-5 · Cited by 1,362
“uitination of the intact virus can occur during transport to the nucleus [73].”
BackgroundAdeno-associated Virus Serotypes: Vector Toolkit for Human Gene Therapy
Wu, Z., Asokan, A., & Samulski, R. J. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.05.009 · Cited by 922
Immune responses to AAV vectors: overcoming barriers to successful gene therapy
Mingozzi, F., & High, K. A. (2013) · Blood · doi:10.1182/blood-2013-01-306647 · Cited by 955
“Early studies by Engelhardt and colleagues 89,90 showed that AAV vector particles are indeed ubiquitinated once internalized in the cytosol, a step that is fundamental for targeting intracellular proteins for degradation through More than 50% of humans develop anti-AAV humoral immunity after the…”
Adeno-associated virus as a delivery vector for gene therapy of human diseases
Wang, J.-H., Gessler, D. J., Zhan, W., Gallagher, T. L., & Gao, G. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01780-w · Cited by 904
Emerging issues in AAV-mediated in vivo gene therapy
Colella, P., Ronzitti, G., & Mingozzi, F. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2017.11.007 · Cited by 881
Zhong, L., Li, B., Mah, C. S., Govindasamy, L., Agbandje-McKenna, M., Cooper, M., Herzog, R. W., Zolotukhin, I., Warrington, K. H., Weigel-Van Aken, K. A., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0802866105 · Cited by 558
“In addition, it is also possible that the proteasome effect may be cell type-specific (31, 39, 40).”
BackgroundSelf-complementary AAV vectors; advances and applications
McCarty, D. M. (2008) · Molecular Therapy · doi:10.1038/mt.2008.171 · Cited by 515
Wang, Z., Ma, H.-I., Li, J., Sun, L., Zhang, J., & Xiao, X. (2003) · Gene Therapy · doi:10.1038/sj.gt.3302133 · Cited by 367
High-efficiency transduction of the mouse retina by tyrosine-mutant AAV serotype vectors
Petrs-Silva, H., Dinculescu, A., Li, Q., Min, S.-H., Chiodo, V., Pang, J.-J., Zhong, L., Zolotukhin, S., Srivastava, A., Lewin, A. S., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2008.269 · Cited by 398
Identification of a heparin-binding motif on adeno-associated virus type 2 capsids
Kern, A., Schmidt, K., Leder, C., Müller, O. J., Wobus, C. E., Bettinger, K., Von der Lieth, C. W., King, J. A., & Kleinschmidt, J. A. (2003) · Journal of Virology · doi:10.1128/jvi.77.20.11072-11081.2003 · Cited by 380
“As postbinding events have a strong influence on gene transduction (15, 20, 27, 55, 71, 73), a particular mutation could compensate for a defect in cell binding and entry by improved cytoplasmic and nuclear trafficking or even replication and assembly.”
BackgroundBinding of Adeno-associated Virus Type 5 to 2,3-Linked Sialic Acid Is Required for Gene Transfer
Walters, R. W., Yi, S. M. P., Keshavjee, S., Brown, K. E., Welsh, M. J., Chiorini, J. A., & Zabner, J. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m101559200 · Cited by 363
Grimm, D., & Kay, M. (2003) · Current Gene Therapy · doi:10.2174/1566523034578285 · Cited by 350
“In the second study, Yan and coworkers [2002] demonstrated that similar to AAV-2 [Duan et al., 2000], AAV-5 capsids become ubiquitinated in cells and subsequently degraded by the proteasome machinery.”
BackgroundUnrestricted Hepatocyte Transduction with Adeno-Associated Virus Serotype 8 Vectors in Mice
Nakai, H., Fuess, S., Storm, T. A., Muramatsu, S.-I., Nara, Y., & Kay, M. A. (2005) · Journal of Virology · doi:10.1128/jvi.79.1.214-224.2005 · Cited by 327
“Such barriers include endosomal processing and viral coat modification, which involves the ubiquitin/proteasome system (9, 19), cytoplasmic trafficking (48, 50), nuclear entry, uncoating (54), conversion from single-stranded to double-stranded vector genomes (11, 12, 38), processing of doublestranded vector genomes in…”
BackgroundMartin, M. E., & Rice, K. G. (2007) · The AAPS Journal · doi:10.1208/aapsj0901003 · Cited by 319
Halbert, C. L., Allen, J. M., & Miller, A. D. (2001) · Journal of Virology · doi:10.1128/jvi.75.14.6615-6624.2001 · Cited by 314
“influence the efficiency of AAV vectors (9).”
Kobinger, G. P., Weiner, D. J., Yu, Q.-C., & Wilson, J. M. (2001) · Nature Biotechnology · doi:10.1038/85664 · Cited by 307
“Indeed, AAV-2 has been shown to proceed through different post-entry steps when entering polarized airway cells apically or basolaterall”
BackgroundSonntag, F., Bleker, S., Leuchs, B., Fischer, R., & Kleinschmidt, J. A. (2006) · Journal of Virology · doi:10.1128/jvi.01056-06 · Cited by 280
“although ubiquitylation and ubiquitin-dependent degradation of AAV2 and AAV5 capsids have been demonstrated (16, 75).”
BackgroundDouar, A.-M., Poulard, K., Stockholm, D., & Danos, O. (2001) · Journal of Virology · doi:10.1128/jvi.75.4.1824-1833.2001 · Cited by 282
“have recently reported an enhancing effect of antiproteasome treatments on rAAV-mediated transduction (8).”
BackgroundSanlioglu, S., Benson, P. K., Yang, J., Atkinson, E. M., Reynolds, T., & Engelhardt, J. F. (2000) · Journal of Virology · doi:10.1128/jvi.74.19.9184-9196.2000 · Cited by 269
Self-citationDuan, D., Yue, Y., & Engelhardt, J. F. (2001) · Molecular Therapy · doi:10.1006/mthe.2001.0456 · Cited by 262
“The pCisRSVLacZ plasmid contains the full-length prokaryotic lacZ gene under the transcriptional control of the RSV promoter and the SV40 poly(A) [27].”
BackgroundMethodInfluentialSelf-citationCapsid modifications for targeting and improving the efficacy of AAV vectors
Büning, H., & Srivastava, A. (2019) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2019.01.008 · Cited by 260
“Subsequently, Duan et al.89 reported that AAV2 capsids become ubiquitinated in the cytoplasm and targeted for degradation by the host cell proteasomal machinery.”
BackgroundIntracellular transport of recombinant adeno-associated virus vectors
Nonnenmacher, M., & Weber, T. (2012) · Gene Therapy · doi:10.1038/gt.2012.6 · Cited by 258
Intracellular trafficking of adeno-associated viral vectors
Ding, W., Zhang, L., Yan, Z., & Engelhardt, J. F. (2005) · Gene Therapy · doi:10.1038/sj.gt.3302527 · Cited by 251
Self-citationFlotte, T. R., Zeitlin, P. L., Reynolds, T. C., Heald, A. E., Pedersen, P., Beck, S., Conrad, C. K., Brass-Ernst, L., Humphries, M., Sullivan, K., et al. (2003) · Human Gene Therapy · doi:10.1089/104303403322124792 · Cited by 246
“Recent studies indicate that entry of AAV2 into bronchial epithelial cells at the apical surface occurs via enters a heparin-sulfate independent pathway that results in prolonged transit time through the cytoplasm and susceptibility to proteosome-mediated degradation (Duan et al ., 2000).”
Davidoff, A. M., Ng, C. Y. C., Zhou, J., Spence, Y., & Nathwani, A. C. (2003) · Blood · doi:10.1182/blood-2002-09-2889 · Cited by 244
Aitken, M. L., Moss, R. B., Waltz, D. A., Dovey, M. E., Tonelli, M. R., McNamara, S. C., Gibson, R. L., Ramsey, B. W., Carter, B. J., & Reynolds, T. C. (2001) · Human Gene Therapy · doi:10.1089/104303401753153956 · Cited by 239
“This might be ameliorated by concurrent administration of proteasome inhibitors that can increase transduction in the lung by 10-to 100-fold (Duan et al ., 2000).”
Zhong, L., Li, B., Jayandharan, G., Mah, C. S., Govindasamy, L., Agbandje-McKenna, M., Herzog, R. W., Weigel-Van Aken, K. A., Hobbs, J. A., Zolotukhin, S., et al. (2008) · Virology · doi:10.1016/j.virol.2008.08.027 · Cited by 232
“…Ub/proteasome pathway has previously been shown to play an essential role in AAV2 nuclear transport (Ding et al., 2005, 2006; Douar et al., 2001; Duan et al., 2000), our data also provide direct evidence that EGFR-PTK-mediated tyrosine-phosphorylation of AAV2 capsids leads to ubiquitination,…”
BackgroundInfluentialRecombinant Adeno-associated Virus Transduction and Integration
Schultz, B. R., & Chamberlain, J. S. (2008) · Molecular Therapy · doi:10.1038/mt.2008.103 · Cited by 215
Venkatakrishnan, B., Yarbrough, J., Domsic, J., Bennett, A., Bothner, B., Kozyreva, O. G., Samulski, R. J., Muzyczka, N., McKenna, R., & Agbandje-McKenna, M. (2013) · Journal of Virology · doi:10.1128/jvi.02524-12 · Cited by 225
Efficient and Selective AAV2-Mediated Gene Transfer Directed to Human Vascular Endothelial Cells
Nicklin, S. A., Buening, H., Dishart, K. L., de Alwis, M., Girod, A., Hacker, U., Thrasher, A. J., Ali, R. R., Hallek, M., & Baker, A. H. (2001) · Molecular Therapy · doi:10.1006/mthe.2001.0424 · Cited by 219
Yan, Z., Zak, R., Luxton, G. W. G., Ritchie, T. C., Bantel-Schaal, U., & Engelhardt, J. F. (2002) · Journal of Virology · doi:10.1128/jvi.76.5.2043-2053.2002 · Cited by 222
“It was previously demonstrated that AAV-2 capsid proteins are ubiquitinated in primary fibroblasts and that LLnL treatment augments rAAV transgene expression 10-fold in this cell type (12).”
BackgroundMethodResultInfluentialSelf-citationAAV Capsid Structure and Cell Interactions
Agbandje-McKenna, M., & Kleinschmidt, J. (2012) · Methods in Molecular Biology · doi:10.1007/978-1-61779-370-7_3 · Cited by 215
Gene Therapy for Duchenne Muscular Dystrophy
Elangkovan, N., & Dickson, G. (2021) · Journal of Neuromuscular Diseases · doi:10.3233/jnd-210678 · Cited by 196
“The tropism of the viral capsids are largely due to presence of respective viral receptors on target cells, which can vary between species [43, 44].”
BackgroundEntry of viruses through the epithelial barrier: pathogenic trickery
Bomsel, M., & Alfsen, A. (2003) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1005 · Cited by 196
Yang, G. S., Schmidt, M., Yan, Z., Lindbloom, J. D., Harding, T. C., Donahue, B. A., Engelhardt, J. F., Kotin, R., & Davidson, B. L. (2002) · Journal of Virology · doi:10.1128/jvi.76.15.7651-7660.2002 · Cited by 204
“AAV2 vectors efficiently internalize from the apical surface of differentiated human airway epithelia but achieve poor transgene expression, in part due to ubiquitination of the AAV capsid after virion internalization and endosomal release (13).”
BackgroundSelf-citationRecent developments in adeno‐associated virus vector technology
Büning, H., Perabo, L., Coutelle, O., Quadt‐Humme, S., & Hallek, M. (2008) · The Journal of Gene Medicine · doi:10.1002/jgm.1205 · Cited by 187
“Initially, a lack of receptors was thought to be responsible for this difference, but data now point towards impaired trafficking and nuclear transport as the virions try to enter from the apical cell surface [44].”
BackgroundAdeno-Associated Virus Vectorology, Manufacturing, and Clinical Applications
Grieger, J. C., & Samulski, R. J. (2012) · Methods in Enzymology · doi:10.1016/b978-0-12-386509-0.00012-0 · Cited by 199
“…double-stranded DNA prior to gene expression (Ferrari et al., 1996; Fisher et al., 1996) Studies have revealed additional bottlenecks that include rAAV transport to the nucleus and/or uncoating from the capsid (Duan et al., 2000; Johnson and Samulski, 2009; Sipo et al., 2007; Thomas et al., 2004).”
BackgroundTargeted Gene Delivery to Vascular Tissue In Vivo by Tropism-Modified Adeno-Associated Virus Vectors
White, S. J., Nicklin, S. A., Büning, H., Brosnan, M. J., Leike, K., Papadakis, E. D., Hallek, M., & Baker, A. H. (2004) · Circulation · doi:10.1161/01.cir.0000109697.68832.5d · Cited by 193
Pien, G. C., Basner-Tschakarjan, E., Hui, D. J., Mentlik, A. N., Finn, J. D., Hasbrouck, N. C., Zhou, S., Murphy, S. L., Maus, M. V., Mingozzi, F., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci36891 · Cited by 192
“It has been demonstrated that ubiquitination of AAV capsid proteins occurs after endocytosis (28, 29) and is facilitated by EGFR-PTK signaling (30).”
BackgroundAAV hybrid serotypes: improved vectors for gene delivery
Choi, V., McCarty, D., & Samulski, R. (2005) · Current Gene Therapy · doi:10.2174/1566523054064968 · Cited by 191
Greber, U. F. (2002) · Cellular and Molecular Life Sciences CMLS · doi:10.1007/s00018-002-8453-3 · Cited by 186
“Interestingly, incoming AAV-2 is ubiquitinated and degraded by the proteasome [206; 207].”
BackgroundImmunity to adeno-associated virus vectors in animals and humans: a continued challenge
Zaiss, A. K., & Muruve, D. A. (2008) · Gene Therapy · doi:10.1038/gt.2008.54 · Cited by 180
Molecular evolution of adeno-associated virus for enhanced glial gene delivery
Koerber, J. T., Klimczak, R., Jang, J.-H., Dalkara, D., Flannery, J. G., & Schaffer, D. V. (2009) · Molecular Therapy · doi:10.1038/mt.2009.184 · Cited by 181
Adenovirus and Adeno-Associated Virus Vectors
Lai, C. M., Lai, Y. K. Y., & Rakoczy, P. E. (2002) · DNA and Cell Biology · doi:10.1089/104454902762053855 · Cited by 175
“…that have shown low permissiveness to rAAV transduction are airway epithelial cells, fast muscle fibers, neural progenitor cells, ovarian cancer cells and some hematopoietic cells (Pruchnic et al ., 2000) (Duan et al ., 2000b; Handa et al ., 2000; Hughes et al ., 2002; Vermeij et al ., 2001).”
InfluentialAdeno-associated viral vector-mediated immune responses: Understanding barriers to gene delivery
Nidetz, N. F., McGee, M. C., Tse, L. V., Li, C., Cong, L., Li, Y., & Huang, W. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107453 · Cited by 174
Gene therapy progress and prospects: cystic fibrosis
Griesenbach, U., Geddes, D. M., Alton, E. W. F. W., & on behalf of the UK Cystic Fibrosis Gene Therapy Consortium (2006) · Gene Therapy · doi:10.1038/sj.gt.3302809 · Cited by 175
Grieger, J. C., Snowdy, S., & Samulski, R. J. (2006) · Journal of Virology · doi:10.1128/jvi.02723-05 · Cited by 172
Enhancement of Adeno-Associated Virus Infection by Mobilizing Capsids into and Out of the Nucleolus
Johnson, J. S., & Samulski, R. J. (2009) · Journal of Virology · doi:10.1128/jvi.02309-08 · Cited by 162
“As previously reported, proteasome inhibitors and genotoxic agents affect events of subcellular processing to enhance transduction of rAAV2 in a cell type- and serotype-specific manner (16, 20, 27, 29).”
BackgroundInfluentialEvidence for the Failure of Adeno-associated Virus Serotype 5 to Package a Viral Genome ≥8.2 kb
Lai, Y., Yue, Y., & Duan, D. (2010) · Molecular Therapy · doi:10.1038/mt.2009.256 · Cited by 166
Self-citationBarriers to and new approaches for gene therapy and gene delivery in cystic fibrosis
Ferrari, S., Geddes, D. M., & Alton, E. W. F. W. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00145-x · Cited by 166
Gene Therapy Progress and Prospects: Recombinant adeno-associated virus (rAAV) vectors
Flotte, T. R. (2004) · Gene Therapy · doi:10.1038/sj.gt.3302233 · Cited by 158
Martino, A. T., Basner-Tschakarjan, E., Markusic, D. M., Finn, J. D., Hinderer, C., Zhou, S., Ostrov, D. A., Srivastava, A., Ertl, H. C. J., Terhorst, C., et al. (2013) · Blood · doi:10.1182/blood-2012-10-460733 · Cited by 162
“Proteasome inhibition has been shown to reduce MHC I presentation of capsid antigen, prevent killing byCTLs, and also increase transduction/transgene expression from AAV vectors.(22,32,41) Pretreatment of target H2.”
BackgroundImmunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer
Arjomandnejad, M., Dasgupta, I., Flotte, T. R., & Keeler, A. M. (2023) · BioDrugs · doi:10.1007/s40259-023-00585-7 · Cited by 159
“In vitro and preclinical animal studies have shown administration of bortezomib prevents degradation of internalized AAVs, reduces capsid presentation, and increases transduction efficiency by enhancing nuclear translocation of AAV [165, 224, 225].”
BackgroundLux, K., Goerlitz, N., Schlemminger, S., Perabo, L., Goldnau, D., Endell, J., Leike, K., Kofler, D. M., Finke, S., Hallek, M., et al. (2005) · Journal of Virology · doi:10.1128/jvi.79.18.11776-11787.2005 · Cited by 152
“The endocytotic process and the subsequent trafficking steps are still poorly understood and may differ substantially in different cell types, and in some cases even in the same cell types (7, 16).”
BackgroundTailoring the AAV vector capsid for gene therapy
Vandenberghe, L. H., Wilson, J. M., & Gao, G. (2009) · Gene Therapy · doi:10.1038/gt.2008.170 · Cited by 155
Treatment of human disease by adeno-associated viral gene transfer
Warrington, K. H., & Herzog, R. W. (2006) · Human Genetics · doi:10.1007/s00439-006-0165-6 · Cited by 155
“Proteasomal degradation limits transfer of the vector from endosomes to the nucleus, which can be blocked by certain antibiotics and other proteasome inhibitors (Duan et al. 2000b).”
BackgroundAllay, J. A., Sleep, S., Long, S., Tillman, D. M., Clark, R., Carney, G., Fagone, P., McIntosh, J. H., Nienhuis, A. W., Davidoff, A. M., et al. (2011) · Human Gene Therapy · doi:10.1089/hum.2010.202 · Cited by 152
“…al., 1997; Herzog et al., 1999), retinal photoreceptor cells (Flannery et al., 1997; Ali et al., 2000), bronchial epithelium (Wagner et al., 1999a; Duan et al., 2000; Halbert et al., 2000), and hepatocytes (Snyder et al., 1999; Nathwani et al., 2001, 2002), resulting in long-term transgene…”
BackgroundNoninvasive gene transfer to the lung for systemic delivery of therapeutic proteins
Auricchio, A., O’Connor, E., Weiner, D., Gao, G.-P., Hildinger, M., Wang, L., Calcedo, R., & Wilson, J. M. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15780 · Cited by 136
“Although there has been some success using AAV2-based vectors in the lung (13), most experiments with AAV2 gene delivery to airway epithelial cells from the luminal side have been disappointing (14, 15).”
BackgroundZhong, L., Zhao, W., Wu, J., Li, B., Zolotukhin, S., Govindasamy, L., Agbandje-McKenna, M., & Srivastava, A. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300170 · Cited by 146
Adenovirus-Facilitated Nuclear Translocation of Adeno-Associated Virus Type 2
Xiao, W., Warrington, K. H., Hearing, P., Hughes, J., & Muzyczka, N. (2002) · Journal of Virology · doi:10.1128/jvi.76.22.11505-11517.2002 · Cited by 137
“duction in all cell types (8), and it is now clear that there may be alternative trafficking methods.”
BackgroundGrieger, J. C., & Samulski, R. J. (2005) · Advances in biochemical engineering, biotechnology · doi:10.1007/10_005 · Cited by 159
A Capsid-Encoded PPxY-Motif Facilitates Adenovirus Entry
Wodrich, H., Henaff, D., Jammart, B., Segura-Morales, C., Seelmeir, S., Coux, O., Ruzsics, Z., Wiethoff, C. M., & Kremer, E. J. (2010) · PLoS Pathogens · doi:10.1371/journal.ppat.1000808 · Cited by 130
“In contrast, blocking the proteasome increases the transduction efficiency of adenoassociated virus vectors and this correlates with ubiquitylation of capsid proteins [11,12].”
BackgroundAdeno-Associated Viral Vectors and Their Redirection to Cell-Type Specific Receptors
Michelfelder, S., & Trepel, M. (2009) · Advances in genetics · doi:10.1016/s0065-2660(09)67002-4 · Cited by 149
“Consequently, proteasome inhibitors have been used to increase the rate of AAV-2 transduction in certain cell types and tissues (Duan et al., 2000; Grieger and Samulski, 2005; Jennings et al., 2005; Yan et al., 2002).”
BackgroundMethodYan, Z., Zak, R., Zhang, Y., Ding, W., Godwin, S., Munson, K., Peluso, R., & Engelhardt, J. F. (2004) · Journal of Virology · doi:10.1128/jvi.78.6.2863-2874.2004 · Cited by 138
“man polarized epithelia (10, 14) and in vivo in mouse lungs”
BackgroundMethodInfluentialSelf-citationAdvances in gene therapy for cystic fibrosis lung disease
Yan, Z., McCray, P. B., & Engelhardt, J. F. (2019) · Human Molecular Genetics · doi:10.1093/hmg/ddz139 · Cited by 140
“Second, apical transduction of HAE-ALI with rAAV2 encounters a postentry block in nuclear transport of the virion that can be overcome using proteasome inhibitors (44).”
BackgroundSelf-citationMarkusic, D. M., Herzog, R. W., Aslanidi, G. V., Hoffman, B. E., Li, B., Li, M., Jayandharan, G. R., Ling, C., Zolotukhin, I., Ma, W., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2010.172 · Cited by 131
The Mre11/Rad50/Nbs1 complex limits adeno-associated virus transduction and replication
Schwartz, R. A., Palacios, J. A., Cassell, G. D., Adam, S., Giacca, M., & Weitzman, M. D. (2007) · Journal of Virology · doi:10.1128/jvi.01523-07 · Cited by 130
“Proteasome inhibitors were then added approximately 24 h after rAAV application to avoid stimulating transduction through modulation of intracellular trafficking (14, 18).”
BackgroundBantel-Schaal, U., Hub, B., & Kartenbeck, J. (2002) · Journal of Virology · doi:10.1128/jvi.76.5.2340-2349.2002 · Cited by 129
“Site specificity requires expression of one of the large nonstructural AAV2 Rep proteins (1, 58).”
ResultInfluentialHansen, J., Qing, K., & Srivastava, A. (2001) · Journal of Virology · doi:10.1128/jvi.75.9.4080-4090.2001 · Cited by 129
“Moreover, ubiquitination of viral capsids has been postulated as a mechanism whereby certain cell types can degrade the entering virions prior to nuclear translocation (10).”
BackgroundTriple Vectors Expand AAV Transfer Capacity in the Retina
Maddalena, A., Tornabene, P., Tiberi, P., Minopoli, R., Manfredi, A., Mutarelli, M., Rossi, S., Simonelli, F., Naggert, J. K., Cacchiarelli, D., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2017.11.019 · Cited by 128
Recombinant Adeno-Associated Virus Utilizes Host Cell Nuclear Import Machinery To Enter the Nucleus
Nicolson, S. C., & Samulski, R. J. (2014) · Journal of Virology · doi:10.1128/jvi.02660-13 · Cited by 114
Qing, K., Hansen, J., Weigel-Kelley, K. A., Tan, M., Zhou, S., & Srivastava, A. (2001) · Journal of Virology · doi:10.1128/jvi.75.19.8968-8976.2001 · Cited by 126
“Second, endosomal processing has recently been suggested to lead to efficient intracellular trafficking of AAV into the nucleus (6, 7).”
Monahan, P. E., Lothrop, C. D., Sun, J., Hirsch, M. L., Kafri, T., Kantor, B., Sarkar, R., Tillson, D. M., Elia, J. R., & Samulski, R. J. (2010) · Molecular Therapy · doi:10.1038/mt.2010.170 · Cited by 125
Journey to the Center of the Cell: Tracing the Path of AAV Transduction
Dhungel, B. P., Bailey, C. G., & Rasko, J. E. J. (2021) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2020.09.010 · Cited by 122
AAV transcytosis through barrier epithelia and endothelium
Di Pasquale, G., & Chiorini, J. A. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2005.11.007 · Cited by 121
“AAV-2 is reported to enter some barrier epithelia, such as human airway, but traffics to the proteasome where it is targeted for degradation [35].”
BackgroundShi, J., Zheng, D., Liu, Y., Sham, M. H., Tam, P. K. H., Farzaneh, F., & Xu, R. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2749 · Cited by 128
“Nevertheless, despite some success with AAV2-based vectors in the lung (22), the luminal introduction of AAV has had largely disappointing results (23).”
BackgroundVirus strategies for passing the nuclear envelope barrier
Kobiler, O., Drayman, N., Butin‐Israeli, V., & Oppenheim, A. (2012) · Nucleus · doi:10.4161/nucl.21979 · Cited by 126
Finn, J. D., Hui, D., Downey, H. D., Dunn, D., Pien, G. C., Mingozzi, F., Zhou, S., & High, K. A. (2010) · Molecular Therapy · doi:10.1038/mt.2009.257 · Cited by 115
Lombardo, E., Ramírez, J. C., Garcia, J., & Almendral, J. M. (2002) · Journal of Virology · doi:10.1128/jvi.76.14.7049-7059.2002 · Cited by 114
“Interestingly, tissue-specific ubiquitination of the entering adeno-associated virus virions after endocytosis was proposed as a mechanism controlling parvovirus tropism (20).”
BackgroundPajusola, K., Gruchała, M., Joch, H., Lüscher, T. F., Ylä‐Herttuala, S., & Büeler, H. (2002) · Journal of Virology · doi:10.1128/jvi.76.22.11530-11540.2002 · Cited by 124
“studied by using various proteasome inhibitors (7, 9).”
BackgroundJohnson, J. S., Li, C., DiPrimio, N., Weinberg, M. S., McCown, T. J., & Samulski, R. J. (2010) · Journal of Virology · doi:10.1128/jvi.00687-10 · Cited by 105
“have been put forth: they increase the nuclear delivery of AAV (18), increase the ubiquitination of capsids (70), inhibit the clearance of viral capsids, inhibit the clearance of viral genomes (16), and potentiate the accumulation of virions in the nucleolus (33).”
BackgroundPopa-Wagner, R., Porwal, M., Kann, M., Reuss, M., Weimer, M., Florin, L., & Kleinschmidt, J. A. (2012) · Journal of Virology · doi:10.1128/jvi.00282-12 · Cited by 109
“As intracellular trafficking, capsid processing, and nuclear uptake limit AAV’s transduction efficiency, an increasing number of studies have been dedicated to elucidate virus-cell interactions involved in these postentry steps (13, 15, 21, 25, 29, 42, 44, 50, 60, 63, 64).”
BackgroundZentilin, L., Marcello, A., & Giacca, M. (2001) · Journal of Virology · doi:10.1128/jvi.75.24.12279-12287.2001 · Cited by 101
“These events include processing of AAV particles in endosomes, lysosomal escape, nuclear import of the AAV genome (6, 19, 27), and single-stranded DNA genome conversion to long-lasting double-stranded DNA molecules (20, 21).”
BackgroundYan, Z., Zak, R., Zhang, Y., & Engelhardt, J. F. (2005) · Journal of Virology · doi:10.1128/jvi.79.1.364-379.2005 · Cited by 107
“Understanding the mechanisms of AAV intracellular trafficking and the involvement of the ubiquitin/proteasome system has led to methods to improve rAAV transduction by enhancing intracellular processing of the virus with proteasome inhibitors (6, 13, 42).”
MethodSelf-citationrAAV2 traffics through both the late and the recycling endosomes in a dose-dependent fashion
Ding, W., Zhang, L. N., Yeaman, C., & Engelhardt, J. F. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2005.12.002 · Cited by 100
Self-citationWang, J., Xie, J., Lu, H., Chen, L., Hauck, B., Samulski, R. J., & Xiao, W. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702778104 · Cited by 100
Chen, S., Kapturczak, M., Loiler, S. A., Zolotukhin, S., Glushakova, O. Y., Madsen, K. M., Samulski, R. J., Hauswirth, W. W., Campbell-Thompson, M., Berns, K. I., et al. (2005) · Human Gene Therapy · doi:10.1089/hum.2005.16.235 · Cited by 102
“Endosomal acidification and proteasomal activity may, at least in part, account for the limited transduction efficiency of rAAV2 vectors (Duan et al ., 2000; Nicklin et al ., 2001).”
Infection of Purified Nuclei by Adeno-associated Virus 2
Hansen, J., Qing, K., & Srivastava, A. (2001) · Molecular Therapy · doi:10.1006/mthe.2001.0457 · Cited by 95
“Purified Nuclei Contain All of the Factors Required for Viral Entry, Uncoating, and Second-Strand DNA Synthesis Although we and others have established that AAV capsids labeled with either 35S or a Cy3 fluorochrome localize to the nucleus [10,14,17], the integrity of the virions and their ability to uncoat and undergo…”
BackgroundCell-Mediated Immunity to AAV Vectors, Evolving Concepts and Potential Solutions
Basner-Tschakarjan, E., & Mingozzi, F. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00350 · Cited by 95
“At the intracellular level, it has been shown that the capsid is substrate for ubiquitination (66, 67), and that proteasome inhibitors, or mutation of surface exposed tyrosine residues that normally undergo phosphorylation and ubiquitination, enhance transduction by enhancing nuclear uptake of virus (68, 69).”
BackgroundHauck, B., Zhao, W., High, K., & Xiao, W. (2004) · Journal of Virology · doi:10.1128/jvi.78.24.13678-13686.2004 · Cited by 99
“are the barriers for AAV high transduction rates of airway epithelia or muscle (6, 9, 27, 28, 31).”
BackgroundAslanidi, G. V., Rivers, A. E., Ortiz, L., Song, L., Ling, C., Govindasamy, L., Van Vliet, K., Tan, M., Agbandje-McKenna, M., & Srivastava, A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0059142 · Cited by 95
“Consistent with previously published data [13,25,26,27,28,29], whereas ,20% of the genomes from the WT AAV2 vectors, and ,45% of the genomes from the triple-mutant vectors were detected in the nuclear fraction 16 h post-infection, more than 70% of the vector genomes from the quadruple-mutant were detected at the same…”
ResultGhosh, A., Yue, Y., & Duan, D. (2011) · Human Gene Therapy · doi:10.1089/hum.2010.122 · Cited by 95
“The cis-plasmids used for AAV packaging are detailed in Table 1 (Duan et al ., 2000; Ghosh et al ., 2006, 2008).”
Self-citationDogbey, D. M., Torres, V. E. S., Fajemisin, E. A., Mpondo, L., Ngwenya, T., Akinrinmade, O. A., Perriman, A. W., & Barth, S. (2023) · Drug Delivery and Translational Research · doi:10.1007/s13346-023-01362-3 · Cited by 105
“This consequently resulted in a decreased number of viral titres required to achieve infection of target cells [73, 74].”
BackgroundNovel molecular approaches to cystic fibrosis gene therapy
LEE, T. W. R., Matthews, D. A., & Blair, G. E. (2005) · Biochemical Journal · doi:10.1042/bj20041923 · Cited by 108
Enhanced Real-Time Monitoring of Adeno-Associated Virus Trafficking by Virus–Quantum Dot Conjugates
Joo, K.-I., Fang, Y., Liu, Y., Xiao, L., Gu, Z., Tai, A., Lee, C.-L., Tang, Y., & Wang, P. (2011) · ACS Nano · doi:10.1021/nn102651p · Cited by 88
“observed in the intracellular viral genome copy number in infected cells treated with or without MG132 at 24 h postinfection (Figure 6B), which is consistent with the previous reports.(51,54) Additionally, the enhanced transduction could not be a result of a modulation in A RTIC LE”
ResultLi, W., Zhang, L., Johnson, J. S., Zhijian, W., Grieger, J. C., Ping-Jie, X., Drouin, L. M., Agbandje-McKenna, M., Pickles, R. J., & Samulski, R. J. (2009) · Molecular Therapy · doi:10.1038/mt.2009.155 · Cited by 87
Akache, B., Grimm, D., Shen, X., Fuess, S., Yant, S. R., Glazer, D. S., Park, J., & Kay, M. A. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300053 · Cited by 98
“[20] [21] [22] Inside the nucleus, AAV eventually uncoats to release its genome and allow its subsequent transcription and replication.”
BackgroundDeposition and Expression of Aerosolized rAAV Vectors in the Lungs of Rhesus Macaques
Beck, S. E., Laube, B. L., Barberena, C. I., Fischer, A. C., Adams, R. J., Chesnut, K. A., Flotte, T. R., & Guggino, W. B. (2002) · Molecular Therapy · doi:10.1006/mthe.2002.0698 · Cited by 86
Ellis, B. L., Hirsch, M. L., Porter, S. N., Samulski, R. J., & Porteus, M. H. (2013) · Gene Therapy · doi:10.1038/gt.2011.211 · Cited by 84
Metadata
- Authors
- Duan, D., Yue, Y., Yan, Z., Yang, J., & Engelhardt, J. F.
- Affiliations
- University of Iowa (US)
- Corresponding author
- Engelhardt, John F.
- Venue
- Journal of Clinical Investigation
- Published
- 2000-06-01
- Volume
- 105
- Issue
- 11
- Pages
- 1573-1587
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC300848
- OpenAlex
- W1970138286
- Cited by
- 391
- References
- 45
- Citations by year
- 2026: 4 · 2025: 10 · 2024: 10 · 2023: 12 · 2022: 8 · 2021: 5 · 2020: 9 · 2019: 17 · 2018: 6 · 2017: 9 · 2016: 4 · 2015: 11 · 2014: 10 · 2013: 18 · 2012: 18
- FWCI
- 13.93
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (DK54759)
- National Heart, Lung, and Blood Institute (R01HL058340)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK54759, P30DK054759)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Cellular transport and secretion
- Keywords
- adeno-associated virus type 2, airway epithelium, endosomal processing, proteasome inhibitors, ubiquitin ligase inhibitors, nuclear trafficking, pulmonary gene therapy, cystic fibrosis
- MeSH terms
- Dependovirus, Animals, Bronchi, Capsid, Cells, Cultured, Cysteine Endopeptidases, Egtazic Acid, Epithelial Cells, Humans, Lung, Mice, Inbred BALB C, Multienzyme Complexes, Endosomes, Ubiquitins, Genetic Therapy, Cell Polarity, Gene Transfer Techniques, Proteasome Endopeptidase Complex, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.